Literature DB >> 27118742

Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's lymphoma.

Jan H Elderman1, Marike Wabbijn1, Felix de Jongh1.   

Abstract

Oncogenic osteomalacia (or tumour-induced osteomalacia) is a rare paraneoplastic syndrome caused by overproduction of fibroblastic growth factor 23 (FGF-23) by tumours. Excessive production of FGF-23 can lead to severe, symptomatic hypophosphataemia. The majority of cases have been associated with benign tumours of bone or soft tissue, such as haemangiopericytomas or other neoplasms of mesenchymal origin. We present a case of a 68-year-old woman with an FGF-23 producing B cell non-Hodgkin's lymphoma. Treatment with immunochemotherapy resulted in normalisation of serum FGF-23 and phosphate levels. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27118742      PMCID: PMC4854165          DOI: 10.1136/bcr-2015-213954

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature.

Authors:  Yan Jiang; Wei-bo Xia; Xiao-ping Xing; Barbara C Silva; Mei Li; Ou Wang; Hua-bing Zhang; Fang Li; Hong-li Jing; Ding-romg Zhong; Jin Jin; Peng Gao; Lian Zhou; Fang Qi; Wei Yu; John P Bilezikian; Xun-wu Meng
Journal:  J Bone Miner Res       Date:  2012-09       Impact factor: 6.741

3.  Oncogenic osteomalacia associated with prostate cancer.

Authors:  D M Reese; P J Rosen
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

4.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

5.  Prostate cancer-induced oncogenic hypophosphatemic osteomalacia.

Authors:  H Nakahama; T Nakanishi; H Uno; T Takaoka; N Taji; O Uyama; O Kitada; M Sugita; A Miyauchi; T Sugishita
Journal:  Urol Int       Date:  1995       Impact factor: 2.089

6.  Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.

Authors:  David E Leaf; Renata C Pereira; Hasan Bazari; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

Review 7.  Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.

Authors:  Fang-Ke Hu; Fang Yuan; Cheng-Ying Jiang; Da-Wei Lv; Bei-Bei Mao; Qiang Zhang; Zeng-Qiang Yuan; Yan Wang
Journal:  Chin J Cancer       Date:  2011-11
  7 in total
  5 in total

Review 1.  Ironing out the cross talk between FGF23 and inflammation.

Authors:  Valentin David; Connor Francis; Jodie L Babitt
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

Review 2.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 3.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

4.  Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature.

Authors:  Constantinos Savva; Jason Adhikaree; Srinivasan Madhusudan; Kamal Chokkalingam
Journal:  J Diabetes Metab Disord       Date:  2019-03-22

5.  Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia.

Authors:  Rachel B Reinert; Dale Bixby; Ronald J Koenig
Journal:  J Endocr Soc       Date:  2018-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.